AUTHOR=Zhou Yongxia , Gao Manzhi , Jing Yaoyao , Wang Xiaofang 

TITLE=Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker

JOURNAL=Frontiers in Genetics

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/genetics/articles/10.3389/fgene.2022.1032382

DOI=10.3389/fgene.2022.1032382

ISSN=1664-8021

ABSTRACT=<p><bold>Background:</bold> IGSF10 is a member of the immunoglobulin superfamily. Over the previous decade, growing proof has validated definitive correlations between individuals of the immunoglobulin superfamily and human diseases. However, the function of <italic>IGSF10</italic> in pan-cancer stays unclear. We aimed to analyze the immunological and prognostic value of <italic>IGSF10</italic> in pan-cancer.</p><p><bold>Methods:</bold> We utilized a vary of bioinformatic ways to inspect the function of <italic>IGSF10</italic> in pan-cancer, including its correlation with prognosis, immune cell infiltration, tumor mutational burden (TMB), microsatellite instability (MSI), mismatch repair (MMR), DNA methyltransferases, genetic alteration, drug sensitivity, etc.</p><p><bold>Results:</bold> We noticed low expression of <italic>IGSF10</italic> in most cancer types. <italic>IGSF10</italic> expression in tumor samples correlates with prognosis in most cancers. In most cancer types, <italic>IGSF10</italic> expression was strongly related to immune cells infiltration, immune checkpoints, immune modulators, TMB, MSI, MMR, and DNA methyltransferases, among others. Functional enrichment analyses indicated that <italic>IGSF10</italic> expression was involved in lymphocyte differentiation, cell molecules adhesion, etc. Furthermore, low <italic>IGSF10</italic> expression could increase the drug sensitivity of many drugs.</p><p><bold>Conclusion:</bold><italic>IGSF10</italic> could serve as a novel prognostic marker and attainable immunotherapy target for several malignancies.</p>